Free press releases distribution network?

Agency / Source: Sinclair & Co.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Bioptigen Named Finalist for Three Prestigious NCTA 21 Awards - Bioptigen has created the commercial market’s deepest spectral domain optical coherence tomography (SDOCT) system for pre-clinical applications - Bioptigen.com
Bioptigen Named Finalist for Three Prestigious NCTA 21 Awards

 

PRZOOM - /newswire/ - Raleigh, NC, United States, 2011/10/06 - Bioptigen has created the commercial market’s deepest spectral domain optical coherence tomography (SDOCT) system for pre-clinical applications - Bioptigen.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The ophthalmic imaging device company, Bioptigen Inc., has been named a finalist in three categories of the 2011 NCTA 21 Awards.

The NCTA 21 Awards are recognized as North Carolina’s largest and most prestigious awards devoted to promoting and celebrating innovation and high-tech excellence throughout the state. The annual showcase honors 21 companies and individuals representing the best and brightest in technology and business, and demonstrating outstanding leadership and innovation.

Bioptigen has created the commercial market’s deepest spectral domain optical coherence tomography (SDOCT) system for pre-clinical applications. NCTA named Bioptigen a finalist in the following award categories: Most Innovative Technology Company, Private Company Excellence, and Small Technology Stage of Development.

“To be named a NCTA 21 Awards finalist alongside the finest of North Carolina’s growing and established firms is exciting for everyone at Bioptigen,” said Dr. Eric Buckland, president and CEO. “I am proud of our employees and the passion they pour every day into developing revolutionary technologies that offer the potential to change our understanding of eye disease and treatment.”

The North Carolina Technology Association (NCTA) is a not-for-profit, membership-driven trade organization that serves as the primary voice for the state’s growing information technology industry.

Bioptigen’s high-performance optical imaging technologies support researchers and clinicians in the study of eye pathologies. The company’s Envisu™ spectral domain ophthalmic imaging platform employs low-power incoherent light to generate high-resolution, depth-resolved images of ocular tissues. Envisu rapidly acquires and displays volumetric images suitable for real-time exploration of tissue physiology and pathology.

Deployed in nine of the top 10 ophthalmic research institutions in the country, Bioptigen’s innovations are covered by more than 60 patent applications, including 30 awarded patents. Researchers and clinicians have published more than 100 scientific articles supported by data acquired through the use of the company’s technologies.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Sinclair & Co.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Bioptigen Named Finalist for Three Prestigious NCTA 21 Awards

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Karen Stinneford - Sinclair-Co.com 
919-833-9102 kstinneford[.]sinclair-co.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Sinclair & Co. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Sinclair & Co. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  RightITnow Ltd

Visit  NAKIVO, Inc.

Visit  JobsWare.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today